| 2.28 0.04 (1.79%) | 11-19 16:00 | |||||||||||||
|
|
| Short term | |
|||
| Mid term | ||||
| Targets | 6-month : | 3.05 | 1-year : | 3.56 |
| Resists | First : | 2.61 | Second : | 3.05 |
| Pivot price | 1.98 |
|||
| Supports | First : | 2.09 | Second : | 1.76 |
| MAs | MA(5) : | 2.06 |
MA(20) : | 2 |
| MA(100) : | 2.53 |
MA(250) : | 2.87 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 76.3 |
D(3) : | 54.4 |
| RSI | RSI(14): 57.1 |
|||
| 52-week | High : | 5.88 | Low : | 1.76 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GNLX ] has closed Bollinger Bands are 29.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.32 - 2.33 | 2.33 - 2.34 |
| Low: | 2.09 - 2.1 | 2.1 - 2.11 |
| Close: | 2.26 - 2.28 | 2.28 - 2.29 |
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Tue, 17 Nov 2026
Genelux (NASDAQ:GNLX) Widens Quarterly Loss as Research Spending Climbs - kalkine.ca
Tue, 17 Nov 2026
Genelux Corporation (GNLX) Tops Q3 EPS by 2c - StreetInsider
Mon, 16 Nov 2026
Genelux Q3 Results: Loss widens 9.5% YoY to $(0.23), misses estimates - scanx.trade
Mon, 16 Nov 2026
Genelux Corporation Reports Third Quarter Financial Results and Provides Business Updates - GlobeNewswire
Mon, 16 Nov 2026
Going-concern doubt accompanies $5.1M in net share-sale proceeds at Genelux (GNLX). - Stock Titan
Mon, 16 Nov 2026
Genelux Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 - www.marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 3.653e+007 (%) |
| Held by Institutions | 12.1 (%) |
| Shares Short | 4,100 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.628e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -455 % |
| Return on Assets (ttm) | 275 % |
| Return on Equity (ttm) | -77.9 % |
| Qtrly Rev. Growth | 8000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -269.6 |
| EBITDA (p.s.) | 12121.2 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 4.17 |
| Dividend | 0 |
| Forward Dividend | 4.64e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |